Moderna-Merck Cancer Vaccine Hits Major Milestone in Phase 3 Trial
Moderna and Merck have achieved a significant milestone in cancer treatment after their jointly developed mRNA vaccine demonstrated promising results in a Phase 3 trial.
The trial, which enrolled over 1,100 patients with melanoma whose tumors had been completely removed by surgery, showed that patients who received the personalized vaccine alongside Keytruda experienced longer periods before their cancer returned and spread to other parts of the body compared to those who received Keytruda alone.
Moderna CEO Stéphane Bancel described the results as 'a big moment for medicine, a big moment for patients.'
The success of this treatment has the potential to revolutionize cancer care by providing a more personalized approach that targets specific mutations in tumors.